Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Acronyms BLESSI
- Sponsors Croma Pharma
- 01 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 17 Feb 2016 New trial record